Blood collector Vitalant reported on Thursday a critical shortage of blood as supplies have been significantly impacted by the COVID-19 pandemic.
Since early March, shelter-in-place orders have resulted in a loss of 150,000 uncollected blood donations, while the resumption of surgeries and other medical procedures have caused a 25% increase in the need for blood in the past several weeks.
Calling on donors to alleviate the shortage, Vitalant said that all blood types are critically needed right now, with an especially high need for type O, A-negative and B-negative red blood cells. In addition, platelets are always needed by patients for cancer treatments, surgeries and emergencies. Because of a short shelf life of just five days, the supply of platelets must be continually replenished.
Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit
Daiichi Sankyo and AstraZeneca launch phase 3 trial of Datroway in high-risk bladder cancer
Inify Laboratories launches UK operations with first NHS agreement
Senhwa completes enrolment in Phase 1b expansion trial of CX-5461
McKesson to acquire Precision Medicine Group for approximately USD2.25bn
Astellas doses first patient in Phase 3 study of ASP2138
Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe
GSK's Jemperli wins FDA priority review for advanced rectal cancer
Leads Biolabs NDA for Opamtistomig accepted by China's CDE
Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance